Oncocytoma, Renal Cancer
Conditions
Brief summary
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Interventions
DIAGNOSTIC_TESTGaGnostic
Plasma
Sponsors
Lund University
Elypta
Zealand University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer. 2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen) 3. Sign up information consent 4. Can perform protocol procedure
Exclusion criteria
1. Non-clear cell Renal cell carcinoma 2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney 3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To identify the optimal GAG score | 2 years | To identify the optimal GAG score in RCC patients |
Countries
Denmark
Outcome results
None listed